Iceni Labs, Macsim Associates sign ‘Mathematics for Innovation’ MoU
2nd February, 2021
FOR IMMEDIATE RELEASE
Iceni Labs and Macsim Associates have signed a Memorandum of Understanding (MoU) to collaborate on projects which require mathematical modelling, data science methods and machine learning algorithms to advance the development of Iceni Labs’ SafeScan technology.
Macsim Associates provides bespoke scientific support services for innovation partners through the early stages of the technology readiness scale. The organisation is led by Dr Cristina V. Sargent, Founder and CEO and Royal Society Entrepreneur in Residence; and Dr Florencia Tettamanti Boshier, Director.
Under the MoU, Macsim Associates will build mathematical models and algorithms that will support the development of SafeScan’s health monitoring and clinical decision-making capabilities.
SafeScan is a remote vital signs radar sensing system designed to monitor the respiratory rate of patients remotely and continuously, including supporting the NHS-recommended National Early Warning Score (NEWS) 2 scoring system which determines the degree of illness of a patient and prompts critical care intervention.
The system is currently undergoing a six month Innovate UK-funded trial at the Royal Papworth Hospital, Cambridge, to test its ability to remotely detect the early deterioration of COVID-19 patients and track their condition so that relevant treatment can be given and overstretched medical resources safeguarded.
Iceni Labs’ priority under the MoU is to enhance the ability of SafeScan to predict patient outcomes at the individual level by applying knowledge gleaned from data collected at the cohort level in order to reveal additional information based on characteristics such as patient age, race and/or existing underlying health conditions. By continually interrogating that data to determine what is ‘normal’ for individuals with certain respiratory, cardio, age, race and health condition markers, health practitioners will have a better chance at identifying those patients who will require intervention earlier, with improved outcomes.
“SafeScan is already an extremely useful piece of kit, offering medical staff the ability to continuously monitor the respiratory rate of patients without requiring the use of cumbersome contact systems or inaccurate ‘spot’ assessment methods,” Alex Giles, Chief Commercial Officer, Iceni Labs, said. “What we want to do now is take this technology to the next level, make it smarter, and better able to support medical staff in determining which patients need specific support as early as possible, and we are grateful to have Macsim Associates on board to help us do that.”
Dr Cristina V. Sargent, Macsim Associates, added: “Our customised data analysis, modelling and machine learning algorithms coupled with Iceni Labs’ outstanding technology will enable us to develop high value applications for health care optimisation, risk analysis, care pathway simulation, scenario generation and decision-making."
Image: SafeScan medical is comprised of two parts: the sensor unit and screen interface unit. About Iceni Labs: Founded in 2013, Iceni Labs is committed to developing and deploying cutting-edge technologies and science to build a safer and more secure tomorrow. Since our founding, we’ve worked on a wide range of innovative projects across broad sectors. We have partnered with the UK National Health Service’s Royal Papworth Hospital to accelerate the development of a non-contact device for monitoring vital signs of patients remotely. The common thread of our technologies is how they reflect our commitment to developing science and technologies for greater human security. From our facilities in London, Dundee and Boston, MA, we operate globally to deliver Mission Critical Science for a safer tomorrow. About Macsim Associates: Founded in 2017, Macsim Associates provide bespoke mathematical services and support innovation happening at the intersection between academia and industry. Our activities are focused on bridging gaps between research, commercial success and benefits to our society. We collaborate with a wide network of associated scientists, senior mathematicians and physicists, from industry and academia. Please direct media enquiries to Claire Apthorp +44 (0) 7920403068 email@example.com